Skip to content
Markets
SPY760.75▼ -1.12%QQQ697.33▼ -2.52%DIA520.89▼ -0.35%GLD359.61▼ -2.43%TLT81.75▲ +0.31%BABA98.90▼ -0.64%NIO3.24▼ -2.41%PDD80.35▲ +1.35%Realtime derived data
Octans ResearchOCTANS RESEARCHWaitlist
Looking up at 14 Wall Street and neighboring office towers in Lower Manhattan's Financial District on a cloudy day.
Source: Jakembradford, CC BY-SA 4.0, via Wikimedia Commons

Dexcom quarterly revenue rises 11.2% to $1.34 billion

Dexcom's revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Oct 29, 2026.

Octans ResearchPublished

Snapshot

Dexcom's revenue growth is slowing: revenue rose 11.2% to $1.34 billion in the quarter ended September 30, 2026, from $1.21 billion a year earlier, after 13.1% year over year growth the quarter before.

Coverage
Independent Research
Prepared by
Octans Research
Tickers
DXCM
As of

Market Data

Latest prices for the companies covered in this article
Company1D %Price
($DXCM)▲ +5.72%84.50

as of 10:03 ET · Realtime derived data

What We Know

Revenue for the quarter ended September 30, 2026 was $1.34 billion, versus $1.21 billion in the same quarter a year earlier, up 11.2%. That is its highest quarterly revenue of the last eight quarters. Diluted earnings per share was $0.72, up from $0.70.

Bar chart: Dexcom: revenue, last eight quarters. US$ billions by fiscal quarter end, as of Oct 29, 2026. Dec 2024 1.11; Mar 2025 1.04; Jun 2025 1.16; Sep 2025 1.21; Dec 2025 1.26; Mar 2026 1.19; Jun 2026 1.31; Sep 2026 1.34. Latest quarter $1.34B, Up 11.2% vs a year earlier.
Source: SEC EDGAR (earnings release and XBRL financial data)

Quarterly revenue by fiscal quarter end, oldest first: Dec 2024: $1.11 billion; Mar 2025: $1.04 billion; Jun 2025: $1.16 billion; Sep 2025: $1.21 billion; Dec 2025: $1.26 billion; Mar 2026: $1.19 billion; Jun 2026: $1.31 billion; Sep 2026: $1.34 billion.

Octans View

Year over year revenue change by quarter, computed from the filed figures: Dec 2025 up 13.1%; Mar 2026 up 15.0%; Jun 2026 up 13.1%; Sep 2026 up 11.2%. On those figures, Dexcom's revenue growth is slowing. That read compares the latest two year over year growth rates and nothing else.

Bear Case · Room for Disagreement

This brief covers reported revenue and diluted earnings per share only. It does not cover guidance, margins, segment results, cash flow or the earnings call, and it makes no forecast. Revenue is the total on the release line we matched; a company's own adjusted measures can differ.

Method and source. Octans Research matched the revenue line in the earnings release (Exhibit 99.1) to the year ago quarter the company reported in its own XBRL financial data; the two must agree before anything is published. The quarterly history comes from the same XBRL data. The text is generated from those verified figures by a fixed template; no model wrote it.

Chart

$DXCM adjusted close, last 6 months $DXCM adjusted close, last 6 months: series rising from 60 to 79.9 (+33.1%) from 2026-05-04 to 2026-10-29. Scale 50 to 100. 5060708090100 2026-05-042026-10-29 $DXCM ADJUSTED CLOSE, LAST 6 MONTHS +33.1% 79.93
Source: Tiingo · As of 2026-10-29Indicative, not investment advice.

Sources

  1. [1]SEC EDGAR — Dexcom earnings release for the quarter ended September 30, 2026 (Exhibit 99.1), filed Oct 29, 2026
  2. [2]SEC EDGAR — Dexcom XBRL financial data (company facts)

These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.

$1.34B

Revenue for the quarter ended September 30, 2026 was $1.34 billion, versus $1.21 billion in the… · What we know

Related coverage

More on $DXCM

4 reports